Linezolid: A new antibiotic for newborns and children?

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 573-581

  Cuzzolin, L ^a   Fanos, Vassilios ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Gram positive pathogens; Linezolid; Newborns; Pediatrics; Staphylococcus aureus

Indexed keywords

CEFADROXIL; LINEZOLID; VANCOMYCIN;

ACUTE OTITIS MEDIA; ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; EOSINOPHILIA; HOSPITAL INFECTION; HUMAN; LOOSE FECES; MEDICAL LITERATURE; METABOLIC ACIDOSIS; NEUTROPENIA; OPTIC NERVE DISEASE; PYREXIA IDIOPATHICA; RASH; REVIEW; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; THRUSH; VOMITING;

EID: 33845994025     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.573     Document Type: Review

References (57)

1. Sohn AH, Garrett DO, Sinkowitz-Cochran RL et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr 2001; 139: 821-827.
2. Brodie SB, Sands KE, Gray JE et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J 2000; 19: 56-65.
3. Stoll BJ, Gordon T, Korones SB et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 72-80.
4. Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infections among infants in a neonatal intensive care unit. Pediatr Infect Dis J 2003; 22: 17-21.
5. Rubin LG, Sanchez PJ, Siegel J et al. Evaluation and treatment of neonates with suspected late-onset sepsis. A survey of neonatologists' practices. Pediatrics 2002; 110: 1-7.
6. Darmstadt GL. Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr Infect Dis J 1997; 16: 227-240.
7. Ladhani S, Garbash M. Staphylococcal skin infections in children. Rational drug therapy recommendations. Pediatr Drugs 2005; 7: 77-102.
8. Kaplan SL, DeVille JG, Yogev R et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-686.
9. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti-Infect Ther 2004; 2: 51-59.
10. Clemeu D, Markham A. Linezolid. Drugs 2000; 59: 815-827.
11. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525-551.
12. Ford C, Hamel J, Stapert D et al. Oxazolidinones: a new class of antimicrobials. Infect Med 1999; 16: 435-445.
13. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyltransferase center. J Mol Biol 1999; 294: 93-101.
14. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
15. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in vitro activity activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721-728.
16. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-1982.
17. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-142.
18. Behra-Miellet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents 2003; 22: 28-34.
19. Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764-767.
20. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47: 1902-1906.
21. Biedenbach DJ, Jones RN. Disk diffusion test interpretative criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol 1997; 35: 3198-3202.
22. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-1846.
23. De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonat Med 2005; 10: 185-194.
24. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50: 73-77.
25. Conte J, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-1480.
26. Shaikh ZH, Peloquin CA, Ericsson CD. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Scand J Infect Dis 2001; 33: 375-379.
27. Weinkers LC et al. In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of the major human metabolite PNU-14258. Am Soc Microbiol (abstr. 11), 1999.
28. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-1246.
29. Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-1145.
30. Lyseng-Williamson KA, Goa KL. Linezolid in infants and children with severe gram-positive infections. Pediatr Drugs 2003; 5: 419-429.
31. Rubinstein E, Isturiz R, Standford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-1831.
32. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21: 1010-1013.
33. Orrick JJ, Johns T, Janelle J, Ramphall R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis 2002; 35: 348-349.
34. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-520.
35. De Vriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111-1117.
36. Kinan A, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: 695-698.
37. Lee E, Burger S, Shah J et al. Linezolid-associated toxic optic neuropathy: a report of two cases. Clin Infect Dis 2003; 37: 1389-1391.
38. Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22: S193-S200.
39. Tan TQ. Update on the use of linezolid. A pediatric perspective. Pediatr Infect Dis J 2004; 23: 955-956.
40. Kearns GL, Abdel-Rahman SM, Blumer JL et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19: 178-184.
41. Kearns GL, Jungbluth GL, Abdel-Rahman SM et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74: 413-422.
42. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22: S153-S157.
43. Zivox (linezolid) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company, 2002.
44. Kaplan SL, Patterson L, Edwards KM et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001; 20: 488-494.
45. Fleishaker DL, Anderson DC, Bruss JB, Chang WH, Todd WM, Hafkin B. Clinical efficacy of linezolid (LZD) in the treatment of otitis media (abstr). Clin Infect Dis 2000; 31: 224.
46. DeVille JG, Adler S, Azimi PH et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22: S158-S163.
47. Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22: 315-322.
48. Yogev R, Patterson LE, Kaplan SL et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22: S172-S177.
49. Jantausch BA, DeVille J, Adler S et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22: S164-S171.
50. Gerson SL, Kaplan SL, Bruss GB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicr Agents Chemother 2002; 46: 2723-2726.
51. Meissner HC, Townsend T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22: S186-S192.
52. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21: 798-799.
53. Ang JY, Lua JL, Turner DR, Asmar BI. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003; 22: 1101-1102.
54. Matson KL, Miller SE. Tooth discoloration after treatment with linezolid. Pharmacotherapy 2003; 23: 682-685.
55. Thomas C, Rosenberg M, Blythe VR, Meyer W. serotonin syndrome and linezolid [letter]. J Am Acad Child Adolesc Psych 2004; 43: 790.
56. Viganò SM, Edefonti A, Ferraresso M et al. Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a pediatric renal transplant recipient. Pediatr Nephrol 2005; 20: 1186-1188.
57. Fanos V, Dall'Agnola A. Antibiotic in neonatal infections. Drugs 1999; 58: 405-427.